Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Leerink Partners cut shares of 10x Genomics (NASDAQ:TXG – Free Report) from an outperform rating to a market perform rating ...

Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of 10x Genomics in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst P. Souda ...

These factors together underpin the positive long-term outlook for 10x Genomics. Souda covers the Healthcare sector, focusing on stocks such as Revvity, Exact Sciences, and Natera. According to ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties 10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations , but sales fell by 10.3% year on year to $165 million. On the other hand, ...